Number of Milestones

No definition available.

Name:	opht_NumberofMilestones
Namespace Prefix:	opht_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount receivable upon achievement of milestone by entity under research and development agreement.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementAggregateAmountReceivableUponAchievementOfMilestone
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of patient enrollment-based milestone revenue achieved by the entity.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementAmountOfEnrollmentBasedMilestoneAchieved
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payments received under the agreement.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementMilestonePaymentsReceived
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of upfront fees received under the agreement.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementUpfrontFeesReceived
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueServicesNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=opht_LicensingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=opht_ResearchAndDevelopmentActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=opht_ActivePharmaceuticalIngredientTransfersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=opht_JointOperatingCommitteeRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=opht_LicensingAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=opht_NovartisPharmaAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=opht_OngoingPerformanceObligationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedPatientEnrollmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedMarketingApprovalMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedCommercialSaleMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licensing and Commercialization Agreement with Novartis Pharma AG (Details) $ in Thousands	1 Months Ended				3 Months Ended		22 Months Ended
	Jun. 30, 2016 USD ($)	Mar. 31, 2015 USD ($)	Sep. 30, 2014 USD ($)	May 31, 2014 USD ($) milestone	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)
Agreement
Total collaboration revenue					$ 1,662	$ 15,721
License revenue
Agreement
Total collaboration revenue					0	0
Research and development activity revenue
Agreement
Total collaboration revenue					1,658	1,275
API transfer revenue
Agreement
Total collaboration revenue					0	14,443
Joint operating committee revenue
Agreement
Total collaboration revenue					4	$ 3
Licensing and Commercialization Agreement \| Novartis Pharma AG
Agreement
Upfront fees received				$ 200,000
Licensing and Commercialization Agreement \| Novartis Pharma AG \| Research and development activity revenue
Agreement
Deferred revenue					208,300
Licensing and Commercialization Agreement \| Novartis Pharma AG \| Research and development activity revenue \| Up-front payment
Agreement
Deferred revenue					200,000
Licensing and Commercialization Agreement \| Novartis Pharma AG \| Research and development activity revenue \| Ongoing performance obligations
Agreement
Deferred revenue					$ 8,300
Licensing and Commercialization Agreement \| Novartis Pharma AG \| Achievement of specified patient enrollment milestones
Agreement
Number of milestones \| milestone				2
Enrollment-based milestone revenue achieved	$ 30,000	$ 50,000	$ 50,000	$ 30,000			$ 130,000
Milestone payment received				130,000			$ 130,000
Licensing and Commercialization Agreement \| Novartis Pharma AG \| Achievement of specified patient enrollment milestones \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone				50,000
Licensing and Commercialization Agreement \| Novartis Pharma AG \| Achievement of specified regulatory approval milestones \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone				300,000
Licensing and Commercialization Agreement \| Novartis Pharma AG \| Achievement of specified commercial sales milestone \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone				$ 400,000